newsfilter
← Latest News
GlobeNewswire·

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that